Corium is a commercial-stage biopharmaceutical company leading the development of new transdermal healthcare products that provide clinicians with important treatment options for patients and their families.
August 4, 2016
Corium Reports Third Quarter Fiscal 2016 Financial Results and Recent Corporate Highlights
“In our third quarter, we made important advances in executing on our business strategy. We achieved key milestones in our Corium-owned Alzheimer’s transdermal product development programs, which represent transformational growth opportunities,” commented Peter D. Staple, President and Chief Executive Officer of Corium.
July 28, 2016
Corium to Report Third Quarter Fiscal Year 2016 Financial Results
Corium International, Inc. (NASDAQ:CORI) today announced that it will report financial results for the third fiscal quarter ended June 30, 2016 on Thursday, August 4, 2016
OUR LEAD PRODUCT
A once-weekly treatment for Alzheimer’s disease, our lead product is a transdermal formulation of donepezil, the active ingredient in Aricept®, which is one of the most commonly prescribed treatments for the care of patients with Alzheimer’s disease. We have demonstrated sustained and controlled delivery of donepezil over a one-week period, with a pharmacokinetic (PK) profile comparable to oral Aricept taken daily for seven days. Learn more